Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice

Table 1 Characteristics of patients with bleeding (n = 686)

Demographic data
Age in years, mean ± SD	77.8 ± 10.8
Men, number (percentage)	368 (53.7)
Weight in kilograms, mean ± SD	72.0 ± 16.2
VKA indication^a, number (percentage)
Non-valvular atrial fibrillation	449 (65.5)
Venous thromboembolic disease	131 (19.1)
Mechanical heart valve	47 (6.9)
Not available	89 (13.0)
Other anticoagulant treatment^b, number (percentage)
Antiplatelet drugs	143 (22)
Outpatient bleeding risk index: Beyth score, number (percentage)
Mild risk	41 (6.0)
Intermediate risk	586 (85.4)
High risk	59 (8.6)
Criteria of severe bleedings (n = 646), number (percentage)
Life-threatening bleeding or organ-compromising bleeding	574 (88.3)
Hemodynamic instability	147 (21.4)
External bleeding uncontrolled with conventional measures	167 (26.3)
Need for red cell transfusion	217 (31.6)
Need for urgent surgery	162 (23.6)

^aMore than one indication was possible; 89 values were missing; ^b36 values were missing. Outpatient bleeding risk index was calculated according to Beyth score [29]. Hemodynamic instability was defined as the presence of one or more of the following criteria: systolic blood pressure (SBP) of less than 90 mm Hg, SBP decrease of at least 40 mm Hg, mean blood pressure of less than 65 mm Hg, or any signs of shock. SD, standard deviation; VKA, vitamin K antagonist.

ISSN: 1364-8535